Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Shares Shorted: Short Interest Down 50.4% in September

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 131,482 shares, a decrease of 50.4% from the August 31st total of 265,115 shares. Based on an average trading volume of 4,781,987 shares, the days-to-cover ratio is currently 0.0 days. Approximately 3.1% of the company’s shares are sold short.

Bluejay Diagnostics Trading Down 9.0%

Bluejay Diagnostics stock traded down $0.08 during trading on Wednesday, hitting $0.85. 395,444 shares of the company were exchanged, compared to its average volume of 2,441,678. The company has a market capitalization of $3.82 million, a P/E ratio of -0.12 and a beta of 0.91. The business’s 50 day moving average is $0.96 and its 200 day moving average is $1.83. Bluejay Diagnostics has a 52 week low of $0.80 and a 52 week high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its earnings results on Wednesday, August 12th. The company reported ($1.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3,520.00) by $3,518.88.

Insider Activity

In related news, major shareholder Financial Lp Hrt acquired 64,047 shares of the stock in a transaction dated Thursday, July 9th. The stock was bought at an average cost of $1.51 per share, for a total transaction of $96,710.97. Following the completion of the transaction, the insider directly owned 126,993 shares of the company’s stock, valued at $191,759.43. The trade was a 101.75% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 6.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Monday, September 21st. Wall Street Zen cut Bluejay Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, September 14th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc is a medical technology company developing rapid, near-patient diagnostic solutions for use in hospitals and other care settings. The company’s focus is on helping clinicians obtain actionable information from small blood samples without relying exclusively on centralized laboratory testing.

Its primary product platform, the Symphony System, combines a reusable analyzer with disposable test cartridges designed to analyze whole-blood biomarkers. The platform’s initial focus has been the Symphony IL-6 Test, which measures interleukin-6, an inflammatory biomarker associated with immune-system activation and conditions such as sepsis.